

Thursday, September 02, 2010

Feedback | Helpdesk | Sign up | Login

▶ EDITORIAL

To print: Click here or Select File and then Print from your browser's menu

BLOW TO STEM CELL RESEARCH

past editorials ...

▶ SERVICES

▼ PHARMA TENDERS & PROJECTS

Tenders&Enquiries

Pharma Projects- NEW

▼ CORPORATE

Company Profiles

Corporate Results

Corporate X-ray

Pharmabiz Studies of Top Companies

Indian Cos Approved by Intl Regulatory Agencies

▼ US FDA UPDATE

US FDA: ANDA

US FDA: Warnings

US FDA: Approved NMEs upto December 2009

US FDA: New Approvals

US approved Labs with Stem Cell Lines

▼ EXPORT & IMPORT

Drug Export Procedures

Drug Registration Norms for Various Countries

Drug Units With WHO GMP Certification

Pharma Export Data

Import Reg Update

▼ PHARMA LAWS & DOCUMENTS

Notifications

Pharma Regulations

Patent Laws and Amendments

Patent Scan

Documents

New Drug Approvals

Notified Prices

List of banned FDCs w.e.f. 01.01.2002

List of formulations containing PPA

List of FDCs of Rifampicin + Isoniazid

▼ LIST OF LABS & GOVT. BODIES

Govt Recognised In-House R&D Units

AICTE Boards & Committees

List of Indian CROs

List of CROs (International)

Govt & approved labs of India

▼ SPECIAL FEATURES

Features

Business of PHARMA MARKETING

▶ Pharma People

**Ecron Acunova reappoints Dr Klaus Wiedey as MD & CEO for Europe operations**

Wednesday, September 01, 2010 15:15 IST  
Our Bureau, Bangalore

Ecron Acunova has announced the reappointment of Dr Klaus D. Wiedey as managing director of EA and CEO Europe. He succeeds Dr Antal Hajos, reassuming the overall responsibility for business, strategic and operational aspects of the European operations.

As founder and CEO of Ecron in Europe, Dr Wiedey led the company for more than 2 decades. He has 35 years experience in the pharmaceutical and CRO industry. Prior to starting Ecron in 1986, Dr Wiedey worked in leading positions at Boehringer Mannheim, Basotherm and Byk-Gulden. He is member of several reputable professional societies and speaker at various international forums. Dr Wiedey is MD with specializations in clinical pharmacology and medical informatics, and he holds a GDPharMed Diploma in Pharmaceutical Medicine

According to DA Prasanna, founder and chairman Ecron Acunova, Dr Wiedey comes with a wealth of experience and is a valuable asset to realize our aspiration of growth plans of EA. "We aim to be a leading CRO accelerating pharma time-to-market cost effectively without compromising on quality."

On his appointment, Dr Wiedey stated that having closely followed the development of EA, the best will be done to keep up the premium quality of services provided by EA's team. This is an opportunity to steer EA to further achievement.

EA is an expert CRO with more than 20 years of track record, offering full-service from phase I-IV clinical research with direct operations in Europe and Asia. As regional experts EA operates each region as a priority market with a European HQ at Frankfurt (Germany) and an Asian HQ at Bangalore (India). EA covers 15 Western & Eastern European countries including Russia & Ukraine. Supplemented by alliance partners, EA offers a well-directed multi-continental geographical spread. Apart from deep competence in conventional clinical research areas like oncology, cardiovascular disease, pulmonology, metabolic disorders, ophthalmology, etc, EA provides unique expertise in diagnostic imaging and stem cell therapy trials.